/PROF
PROF Stock - Profound Medical Corp.
Healthcare|Medical - DevicesNASDAQ
$8.68+0.29%
+$0.03 (+0.29%) • Jan 13
90
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.99
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+38.3%upside
Target: $12.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PROF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$8.59 – $8.76
TARGET (TP)$12.00
STOP LOSS$7.98
RISK/REWARD1:4.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.22
52W High$8.94
52W Low$3.76
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $10.17M | $7.20M | $6.68M | $6.87M | $7.30M |
| Gross Profit | $6.70M | $4.38M | $3.02M | $2.95M | $3.47M |
| Gross Margin | 65.9% | 60.9% | 45.2% | 43.0% | 47.6% |
| Operating Income | $-31,474,571 | $-28,616,000 | $-32,126,000 | $-30,291,000 | $-18,863,000 |
| Net Income | $-26,480,451 | $-28,569,000 | $-28,669,000 | $-30,699,000 | $-21,622,000 |
| Net Margin | -260.4% | -396.8% | -429.1% | -446.7% | -296.0% |
| EPS | $-1.07 | $-1.35 | $-1.38 | $-1.50 | $-1.25 |
Company Overview
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
60%
Hold / Neutral
2
40%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
3 Bullish2 Neutral/Bearish
Price Targets
$50
Average Target
↑ 475.2% Upside
Now
$10
Low
$50
Average
$200
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 23rd 2024 | Lake Street | Initiation | Buy | $16.5 |
| July 16th 2024 | Stifel | Upgrade | Buy | $12← $9 |
| November 28th 2023 | Stifel | Initiation | Hold | $11 |
| August 4th 2023 | Raymond James | Downgrade | Outperform | $200← $20 |
| March 21st 2023 | Jefferies | Downgrade | Hold | $10← $5.5 |
Earnings History & Surprises
PROFBeat Rate
44%
Last 18 quarters
Avg Surprise
-13.6%
EPS vs Estimate
Beats / Misses
8/9
1 met exactly
Latest EPS
$-0.26
Q4 2025
EPS Surprise History
Q1 24
-50.0%
$-0.42vs$-0.28
Q2 24
+16.1%
$-0.26vs$-0.31
Q3 24
0.0%
$-0.28vs$-0.28
Q4 24
-15.2%
$-0.38vs$-0.33
Q1 25
+35.5%
$-0.20vs$-0.31
Q2 25
-24.1%
$-0.36vs$-0.29
Q3 25
-20.9%
$-0.52vs$-0.43
Q4 25
+31.6%
$-0.26vs$-0.38
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | $-0.28 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.38 | $-0.26 | +31.6% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.43 | $-0.52 | -20.9% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.29 | $-0.36 | -24.1% | ✗ MISS |
Q1 2025 | Mar 6, 2025 | $-0.31 | $-0.20 | +35.5% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.33 | $-0.38 | -15.2% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.28 | $-0.28 | 0.0% | = MET |
Q2 2024 | May 9, 2024 | $-0.31 | $-0.26 | +16.1% | ✓ BEAT |
Q1 2024 | Mar 7, 2024 | $-0.28 | $-0.42 | -50.0% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.32 | $-0.26 | +18.8% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.31 | $-0.35 | -12.9% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-0.38 | $-0.32 | +15.8% | ✓ BEAT |
Q1 2023 | Mar 7, 2023 | $0.36 | $-0.46 | -227.8% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.34 | $-0.24 | +29.4% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.42 | $-0.28 | +33.3% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-0.45 | $-0.40 | +11.1% | ✓ BEAT |
Q1 2022 | Mar 3, 2022 | $-0.35 | $-0.49 | -40.0% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.26 | $-0.29 | -11.5% | ✗ MISS |
Q3 2021 | Aug 4, 2021 | $-0.26 | $-0.35 | -34.6% | ✗ MISS |
Latest News
Watching Profound Medical; Hearing Zacks Under $10 Newsletter Mentions Stock As A Buy
📈 PositiveBenzinga•Jan 13, 2026, 04:10 PM
Lake Street Maintains Buy on Profound Medical, Raises Price Target to $12
📈 PositiveBenzinga•Jan 7, 2026, 07:02 PM
Profound Medical Announces First Non‑Trial Prostate Cancer Patient Treated With TULSA‑PRO At Johns Hopkins
📈 PositiveBenzinga•Jan 6, 2026, 01:00 PM
Profound Medical Increases Size Of Previously Announced Private Placement; To Now Raise $6.45M Of 921,428 Shares At $7.00/Share
📈 PositiveBenzinga•Dec 24, 2025, 06:16 PM
Profound Medical Prices $40M Common Stock Offering
➖ NeutralBenzinga•Dec 19, 2025, 01:47 PM
Profound Medical To Launch TULSA-AI Volume Reduction Module For Optimizing Treatment Of Patients With Benign Prostatic Hyperplasia, Or Enlarged Prostate, At RSNA Meeting
📈 PositiveBenzinga•Nov 28, 2025, 12:47 PM
Profound Medical shares are trading lower. The company reported Q3 financial results.
📉 NegativeBenzinga•Nov 13, 2025, 09:18 PM
Profound Medical Q3 EPS $(0.26) Beats $(0.36) Estimate, Sales $5.289M Beat $4.995M Estimate
📈 PositiveBenzinga•Nov 13, 2025, 09:11 PM
Profound Medical Signs Distribution, Supply Agreement For Its TULSA-PRO System With Getz Healthcare In Australia, New Zealand
📈 PositiveBenzinga•Nov 12, 2025, 01:44 PM
Profound Medical inks exclusive Saudi deal for TULSA-PRO and Sonalleve, stock rises
📈 PositiveSeeking Alpha•Nov 12, 2025, 09:18 AM
Profound Medical Enters Into Exclusive Distribution Agreement for TULSA-PRO And Sonalleve With Al Faisaliah Medical Systems In Saudi Arabia
📈 PositiveBenzinga•Nov 11, 2025, 09:18 PM
Profound Medical achieves record prelim revenue for third quarter
📈 PositiveSeeking Alpha•Oct 7, 2025, 01:00 PM
Profound Medical Projects Q3 Revenue of $5.2M - $5.3M, Up 84% - 87% YoY; Gross Margin Expands To 72%
📈 PositiveBenzinga•Oct 7, 2025, 11:47 AM
Profound Medical rises as TULSA procedure launched at Dallas Medical Center
📈 PositiveSeeking Alpha•Sep 23, 2025, 04:58 PM
Frequently Asked Questions about PROF
What is PROF's current stock price?
Profound Medical Corp. (PROF) is currently trading at $8.68 per share. The stock has moved +0.29% today.
What is the analyst price target for PROF?
The average analyst price target for PROF is $12.00, based on 1 analyst.
What sector is Profound Medical Corp. in?
Profound Medical Corp. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is PROF's market cap?
Profound Medical Corp. has a market capitalization of $0.26 billion, making it a small-cap company.
Does PROF pay dividends?
No, Profound Medical Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARMP
Armata Pharmaceuticals, Inc.
$6.28
Mkt Cap: $0.2B
AVR
Anteris Technologies Global Corp.
$4.41
Mkt Cap: $0.1B
CATX
Perspective Therapeutics, Inc.
$2.56
Mkt Cap: $0.2B
LNSR
LENSAR, Inc.
$11.69
Mkt Cap: $0.1B
MXCT
MaxCyte, Inc.
$1.31
Mkt Cap: $0.1B
NNOX
Nano-X Imaging Ltd.
$2.96
Mkt Cap: $0.2B
OWLT
Owlet, Inc.
$14.08
Mkt Cap: $0.2B
PRE
Prenetics Global Limited
$15.88
Mkt Cap: $0.2B
STIM
Neuronetics, Inc.
$1.93
Mkt Cap: $0.1B
TLSI
TriSalus Life Sciences, Inc.
$5.86
Mkt Cap: $0.2B
Explore stocks similar to PROF for comparison